Maxpro Capital Acquisition (JMAC) Competitors $9.50 -0.40 (-4.04%) As of 03/24/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock JMAC vs. ORKA, PRTC, ERAS, SNDL, PHAT, GLUE, RGNX, SIGA, MREO, and HUMAShould you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include Oruka Therapeutics (ORKA), PureTech Health (PRTC), Erasca (ERAS), SNDL (SNDL), Phathom Pharmaceuticals (PHAT), Monte Rosa Therapeutics (GLUE), REGENXBIO (RGNX), SIGA Technologies (SIGA), Mereo BioPharma Group (MREO), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry. Maxpro Capital Acquisition vs. Oruka Therapeutics PureTech Health Erasca SNDL Phathom Pharmaceuticals Monte Rosa Therapeutics REGENXBIO SIGA Technologies Mereo BioPharma Group Humacyte Oruka Therapeutics (NASDAQ:ORKA) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings. Does the media refer more to ORKA or JMAC? In the previous week, Maxpro Capital Acquisition had 1 more articles in the media than Oruka Therapeutics. MarketBeat recorded 2 mentions for Maxpro Capital Acquisition and 1 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 0.00 equaled Maxpro Capital Acquisition'saverage media sentiment score. Company Overall Sentiment Oruka Therapeutics Neutral Maxpro Capital Acquisition Neutral Which has better valuation and earnings, ORKA or JMAC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOruka TherapeuticsN/AN/A-$5.34M-$5.79-2.07Maxpro Capital AcquisitionN/AN/AN/AN/AN/A Which has more volatility & risk, ORKA or JMAC? Oruka Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Do institutionals and insiders believe in ORKA or JMAC? 56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. 22.7% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate ORKA or JMAC? Oruka Therapeutics currently has a consensus target price of $39.86, suggesting a potential upside of 232.42%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Oruka Therapeutics is more favorable than Maxpro Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ORKA or JMAC more profitable? Maxpro Capital Acquisition's return on equity of 0.00% beat Oruka Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Oruka TherapeuticsN/A -24.96% -21.22% Maxpro Capital Acquisition N/A N/A N/A Does the MarketBeat Community favor ORKA or JMAC? Oruka Therapeutics received 17 more outperform votes than Maxpro Capital Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformOruka TherapeuticsOutperform Votes17100.00% Underperform VotesNo VotesMaxpro Capital AcquisitionN/AN/A SummaryOruka Therapeutics beats Maxpro Capital Acquisition on 7 of the 11 factors compared between the two stocks. Remove Ads Get Maxpro Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JMAC vs. The Competition Export to ExcelMetricMaxpro Capital AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$145.16M$450.62M$2.14B$8.32BDividend YieldN/A7.42%2.65%4.02%P/E RatioN/A2.2023.7519.25Price / SalesN/A64.8190.8794.09Price / CashN/A69.01N/A34.64Price / BookN/A3.711.944.46Net IncomeN/A$35.22M-$389.14M$247.07M7 Day Performance19.20%0.89%0.83%3.05%1 Month Performance35.33%-2.09%-1.28%-2.85%1 Year Performance-12.12%8.74%2.39%4.63% Maxpro Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JMACMaxpro Capital AcquisitionN/A$9.50-4.0%N/A-12.1%$145.16MN/A0.002,021Gap UpORKAOruka Therapeutics3.2232 of 5 stars$11.31-1.4%$39.86+252.4%N/A$423.46MN/A-1.81N/APositive NewsPRTCPureTech Health2.0733 of 5 stars$17.55-4.3%$45.00+156.5%-40.7%$420.09M$3.33M0.00100News CoverageERASErasca2.8866 of 5 stars$1.46+1.0%$4.90+236.8%-28.5%$411.37MN/A-1.75120Earnings ReportAnalyst RevisionSNDLSNDL2.8926 of 5 stars$1.56-2.8%$3.25+109.0%-11.0%$408.62M$911.22M-5.02580PHATPhathom Pharmaceuticals3.8268 of 5 stars$5.85+5.5%$22.17+279.2%-38.9%$407.38M$55.25M-1.03110Positive NewsGLUEMonte Rosa Therapeutics2.3794 of 5 stars$6.62-0.7%$15.25+130.4%-33.0%$406.90M$14.98M-3.6290Earnings ReportAnalyst RevisionRGNXREGENXBIO4.4345 of 5 stars$8.23+5.5%$33.88+311.7%-62.0%$406.52M$83.33M-1.63370SIGASIGA Technologies1.6859 of 5 stars$5.65-1.9%N/A-29.5%$403.98M$138.72M4.7140MREOMereo BioPharma Group2.5106 of 5 stars$2.59+2.4%$7.83+202.4%-20.9%$401.05M$1M0.0040Positive NewsHUMAHumacyte2.0855 of 5 stars$3.13+0.1%$13.71+337.6%-8.3%$394.57M$1.57M-2.34150Upcoming EarningsNews CoverageGap Down Remove Ads Related Companies and Tools Related Companies ORKA Competitors PRTC Competitors ERAS Competitors SNDL Competitors PHAT Competitors GLUE Competitors RGNX Competitors SIGA Competitors MREO Competitors HUMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JMAC) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maxpro Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maxpro Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
